BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 24, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

March 31, 2016

View Archived Issues

CMG-101: an mTORC1/2 inhibitor for RCC

Read More

Eli Lilly describes S6K1 inhibitors

Read More

Ono and Santen enter enter licensing agreement for ONO-9054

Read More

FDA grants orphan drug designation to Adaptimmune's T-cell therapy targeting NY-ESO

Read More

Coagadex receives approval in Europe

Read More

FDA grants fast track designation for CA4P

Read More

EMA's COMP backs orphan drug designation for CDNF in ALS

Read More

Inovio announces promising results of human trial evaluating Ebola vaccine

Read More

FDA grants fast track designation for VL-2397 as treatment for invasive aspergillosis

Read More

Kyorin and Kissei sign codevelopment and co-marketing agreement for KRP-114V in Japan

Read More

Shionogi patents HIV protease inhibitors

Read More

Shionogi submits NDAs in Japan and the U.S. for naldemedine

Read More

Janssen Pharmaceutica discloses orexin receptor antagonists

Read More

Neuropore Therapies develops Abeta aggregation inhibitors

Read More

Celgene Avilomics Research divulges MK2 inhibitors

Read More

Esanex reports HSP90 inhibitors

Read More

New phase I/II trial investigates AG-221 or AG-120 with Vidaza for newly diagnosed AML

Read More

Actinium's Iomab-B receives FDA orphan drug designation

Read More

Gilead Sciences applies for approval of tenofovir alafenamide fumarate in Japan

Read More

Radius Health submits NDA for abaloparatide for postmenopausal osteoporosis

Read More

Astellas and Mitsubishi Tanabe to share compound libraries

Read More

FDA approves use of Roche Zika assay to screen blood donations under IND protocol

Read More

aTyr releases phase Ib/II findings for Resolaris in facioscapulohumeral muscular dystrophy

Read More

Lexicon submits NDA for telotristat etiprate to treat carcinoid syndrome

Read More

Establishment of EA Pharma

Read More

FDA approves Defitelio to treat hepatic veno-occlusive disease following HSCT

Read More

PLCB4 overexpression shows promise as a prognostic biomarker in GISTs

Read More

Researchers investigate TrKA inhibitors for the treatment of chronic pain

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 23, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing